Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition
August 18th 2022In response to another opinion piece, Craig Burton, from the Association for Accessible Medicines, argued that the Inflation Reduction Act of 2022 could prevent biosimilar competition, and lower drug prices as a result.
FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar
August 17th 2022The FDA approval of Samsung Bioepis’ high-concentration, citrate-free formulation of Hadlima, a biosimilar referencing Humira (adalimumab), is the first high-concentration adalimumab biosimilar to be approved in the United States.
Study: Biosimilar Uptake, Rather Than Competition, Will Influence Price Decreases
August 15th 2022Researchers found that the percentage of biosimilar uptake is a better predictor of whether prices of biologics will significantly decrease, refuting the argument that more biosimilars for a single reference product will have the biggest impact.
Opinion: Impact of Inflation Reduction Act 2022—Addressing Critics
August 11th 2022Sarfaraz K. Niazi, PhD, a professor, entrepreneur, and biosimilar advocate, took aim at criticisms of the Inflation Reduction Act to 2022 that was passed in the Senate and critiques the argument that the bill should be considered a “price control” measure.
Not So Different: Biosimilars Oncology Roundup for July 2022—Podcast Edition
August 7th 2022On this episode of Not So Different, we recap some of the biggest biosimilars news that happened over the past month, including updates on clinical trials for oncology biosimilars as well as a survey on whether patients were given adequate information prior to switching a biosimilar.
Q&A: How Will Biobetters Fit Into the Growing Biologics Market? Celltrion Executive Explains
August 6th 2022In an interview with The Center for Biosimilars®, Hyoung Ki Kim, vice chairman and CEO of Celltrion Healthcare, breaks down the benefits of biobetters, how they differ from biosimilars, and how they could alter the future landscape of the biologics industry.
FDA Approves Coherus’ Cimerli as Interchangeable Biosimilar to Ranibizumab
August 3rd 2022Another ranibizumab biosimilar, Byooviz, is approved, but Coherus’ product is the first deemed interchangeable, which involves additional FDA requirements that allow substitution without intervention of the prescribing clinician.
Vizient Market Outlook Report Predicts Trends for Adalimumab Biosimilars in 2023
August 2nd 2022Vizient’s Pharmacy Market Outlook report offers predictions on how the emergence of adalimumab biosimilars in 2023 will affect the biosimilar industry and what actions should be taken in advance to ensure biosimilar adoption.
Organon's Jim Carey Shares Thoughts on Biosimilar Legislation, Emerging Adalimumab Products
July 31st 2022Jim Carey, head of US policy and government relations at Organon, a spinoff company from Merck, breaks down strategies to push forward biosimilar legislation, the anticipation for adalimumab biosimilars, and more in this multi-part interview.
Companies Clinch Deals for Global Biosimilar Commercialization
July 26th 2022Prestige Biopharma and Intas Pharmaceuticals join forces to partner on a bevacizumab biosimilar for multiple countries, and Hikma Pharmaceuticals makes a deal with Celltrion Healthcare for the commercialization of an adalimumab biosimilar.
Not So Different: How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab Market
July 24th 2022On this podcast episode, The Center for Biosimilars spoke with Chronis Manolis from UPMC Health Plan to discuss how health care policies may shift as adalimumab biosimilars referencing Humira come to market in 2023, including how providers and payers can ensure equitable access.
Biosimilars Check-In: Celltrion Pushes for Yuflyma in Europe; Xbrane Updates on Ranibizumab Filing
July 21st 2022In recent weeks, Celltrion Healthcare furthered its adalimumab biosimilar (Yuflyma) by launching the drug in Spain and Portugal and starting a clinical trial in France while Xbrane Biopharma provided an update on the FDA filing of its ranibizumab biosimilar.
Alvotech to Launch Pharmacokinetics Study for Denosumab Biosimilar
July 20th 2022The biosimilar candidate would reference Prolia, used in the treatment of osteoporosis in postmenopausal women and to treat bone loss in adult men and women who are at increased risk of fracture. It is also planned as a biosimilar for Xgeva, which is indicated to prevent skeletal fractures in patients with cancer.